-
Anti-cancer Agents in Medicinal... 2024
Topics: Antineoplastic Agents; Humans; Drug Discovery; Neoplasms; Drug Screening Assays, Antitumor; Drug Development
PubMed: 38745440
DOI: 10.2174/187152062404240129164354 -
Clinical Lymphoma, Myeloma & Leukemia Dec 2022AML is a biologically and clinically heterogeneous disease that is associated with poor overall long-term survival. The expanding knowledge of genomic landscape in AML... (Review)
Review
AML is a biologically and clinically heterogeneous disease that is associated with poor overall long-term survival. The expanding knowledge of genomic landscape in AML as well as advancements in molecular and chemical biology over the pathway in AML. After 40 years of stagnancy, the recent approval of numerous novel oral anti-leukemic agents for the treatment of AML has changed both the armamentarium of medications and treatment paradigms. These agents have unique clinical considerations in terms of administration, adverse effects, and monitoring parameters which may differ from clinician's historical expectations. Understanding the data, indication and clinical considerations for such novel oral anti-leukemic agents is paramount for clinicians caring patients with AML.
Topics: Humans; Leukemia, Myeloid, Acute; Antineoplastic Agents
PubMed: 36192350
DOI: 10.1016/j.clml.2022.08.005 -
Journal of Photochemistry and... Oct 2012Most of the clinically used anticancer drugs exert their antitumor effect by damaging the replication machinery of DNA either by covalent or non-covalent binding.... (Review)
Review
Most of the clinically used anticancer drugs exert their antitumor effect by damaging the replication machinery of DNA either by covalent or non-covalent binding. Intercalation and groove fitting are the major modes of non-covalent interaction. Small crescent shaped molecules have been claimed to bind with DNA via minor grooves. A plethora of hybrid molecules based on distamycin or netropsin have been synthesised with the objectives of improved selectivity and specificity with no/reduced unwanted side effects. This review critically and objectively describes the previously known hybrid DNA minor groove binding agents based on five membered, distamycin or netropsin. Moreover, the future use of six-membered benzamides has also been highlighted. Special emphasis has been put on developing structure-activity relationships of DNA minor groove binding agents.
Topics: Animals; Antineoplastic Agents; DNA; Humans; Nucleic Acid Conformation; Organic Chemicals
PubMed: 22857824
DOI: 10.1016/j.jphotobiol.2012.07.003 -
Biochimica Et Biophysica Acta. Reviews... Sep 2022Microtubule targeting agents (MTAs) have attracted extensive attention for cancer treatment. However, their clinical efficacies are limited by intolerable toxicities,... (Review)
Review
Microtubule targeting agents (MTAs) have attracted extensive attention for cancer treatment. However, their clinical efficacies are limited by intolerable toxicities, inadequate efficacy and acquired multidrug resistance. The combination of MTAs with other antineoplastics has become an efficient strategy to lower the toxicities, overcome resistance and improve the efficacies for cancer treatment. In this article, we review the combinations of MTAs with some other anticancer drugs, such as cytotoxic agents, kinases inhibitors, histone deacetylase inhibitors, immune checkpoints inhibitors, to overcome these obstacles. We strongly believe that this review will provide helpful information for combination therapy based on MTAs.
Topics: Antineoplastic Agents; Cytotoxins; Histone Deacetylase Inhibitors; Humans; Microtubules; Neoplasms
PubMed: 35963551
DOI: 10.1016/j.bbcan.2022.188777 -
Revue de L'infirmiere Mar 1985
Topics: Antineoplastic Agents; Humans; Neoplasms
PubMed: 3845666
DOI: No ID Found -
American Journal of Hospital Pharmacy Mar 1993The relationship between occupational exposure to antineoplastic drugs and the presence of acute symptoms of exposure was investigated by questionnaire. Data were...
The relationship between occupational exposure to antineoplastic drugs and the presence of acute symptoms of exposure was investigated by questionnaire. Data were derived from a questionnaire distributed to 8566 pharmacists, pharmacy technicians, nurses, and nurse aids at 57 member institutions of the National Surgical Adjuvant Breast and Bowel Project nationwide. Of the 4659 respondents (54%), 1057 were pharmacists or pharmacy technicians; after exclusions, the sample size was 738. Data were collected on four handling activities: mixing of antineoplastic drugs, administering these drugs, cleaning up spills, and handling patient excreta. Information on mixing was divided into dose, duration, use of protection, and reported skin contact. Respondents indicated which of 27 acute symptoms they had experienced during the past three months. Handling of antineoplastics was associated with a small but significant increase in the number of symptoms compared with controls; reported skin contact was the most important predictor of symptoms. The number of doses handled and the extent of protection were significantly associated with the number of symptoms, but their effect was not independent of that of skin contact. Body mass was significantly associated with the number of symptoms in women but not men. Pharmacists and technicians who handle antineoplastic drugs reported more symptoms associated with exposure than did those who do not handle such agents. All available protective measures should be used.
Topics: Adult; Antineoplastic Agents; Drug Compounding; Female; Humans; Male; Maximum Allowable Concentration; Middle Aged; Occupational Exposure; Personnel, Hospital; Pharmacists; Pharmacy Service, Hospital; Surveys and Questionnaires; United States; Workforce
PubMed: 8442461
DOI: No ID Found -
Biochemical and Biophysical Research... Dec 2014Emerging evidence supports an important, etiologic role for epigenetic modifications in cancer. Various post translational modifications of histone proteins together... (Review)
Review
Emerging evidence supports an important, etiologic role for epigenetic modifications in cancer. Various post translational modifications of histone proteins together with DNA methylation constitute an 'epigenetic code' regulating the transcriptional status of the cell and aberrant writing and/or interpretation of the code can contribute to a dysregulated, hyperproliferative state. In some cases, epigenetic deregulation has also been reported to result in tumor initiation. The discovery of somatic mutations in some chromatin binding proteins associated with subtypes of lymphomas and the ability to regulate expression of proto oncogenes such as Myc has spurred the development of specific small molecule modulators of histone binding proteins. Several of these compounds have entered clinical development for the treatment of heme malignancies. This review summarizes progress in the discovery and advancement of epigenetic therapeutics for cancer and provides a perspective for future development.
Topics: Antineoplastic Agents; Epigenesis, Genetic; Histones; Humans; Neoplasms
PubMed: 25016182
DOI: 10.1016/j.bbrc.2014.07.006 -
Journal of Oncology Pharmacy Practice :... Sep 2009To continue with workplace contamination monitoring in the Alberta Cancer Board (ACB) pharmacy practice environment.
OBJECTIVE
To continue with workplace contamination monitoring in the Alberta Cancer Board (ACB) pharmacy practice environment.
SETTING
The ACB in the Canadian province of Alberta which includes two public tertiary centers and 19 associated community satellite sites based around the province in existing hospitals.
METHODS
After the completion of a Phase 1 and Phase 11 study,(1) which investigated the feasibility of routine monitoring of antineoplastic agent contamination in the pharmacy practice environment, it was decided to launch a Phase III study. The Phase III study would be done at the Cross Cancer Institute in the main pharmacy department as well as at a brand new satellite pharmacy within the CCI hospital. Samples would be taken in these areas as well as on the outer exterior of latex gloves worn to prepare cyclophosphamide and other antineoplastics.
RESULTS
The result determined that the area in front of the biological safety cabinet in the main CCI pharmacy department as well as the exterior of the latex gloves showed evidence of cyclophosphamide contamination. The results from the sample taken in the new satellite pharmacy showed no evidence of cyclophosphamide contamination.
CONCLUSION
results from this study prompted a decision to launch a Phase IV study to determine the feasibility within our network, for routine monitoring as well as sampling throughout the clean room beyond the BSC.
Topics: Alberta; Antineoplastic Agents; Cyclophosphamide; Environmental Monitoring; Environmental Pollution; Gloves, Protective; Occupational Exposure; Pharmacy Service, Hospital
PubMed: 19171554
DOI: 10.1177/1078155208101097 -
Cancer Nursing Aug 1993Antineoplastic drug handling in the absence of adequate protective measures has been associated with biological uptake of the drugs among pharmacists and nurses. This...
Antineoplastic drug handling in the absence of adequate protective measures has been associated with biological uptake of the drugs among pharmacists and nurses. This study investigated the association between occupational exposure to antineoplastics and the presence of acute symptoms in a nationwide sample of 2,048 nurses and nurses' aides. Reported skin contact with the drugs was associated with a small but statistically significant increase in reported symptoms. Although number of doses handled and extent of protection used were significantly associated with number of symptoms, their effect was not independent of skin contact.
Topics: Adult; Antineoplastic Agents; Female; Humans; Middle Aged; Nurses; Nursing Assistants; Occupational Diseases; Occupational Exposure; Protective Clothing
PubMed: 8402605
DOI: No ID Found -
Connecticut Medicine Mar 1976
Review
Topics: Alkaloids; Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Drug Therapy, Combination; Humans; Neoplasms
PubMed: 765057
DOI: No ID Found